RANIR (HOLDINGS) LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. RANIR (HOLDINGS) LIMITED 2012-12-13 → present
2. RANIR LTD. 2010-02-11 → 2012-12-13

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the period to 31 July 2027 and meet its liabilities as they fall due. Accordingly, the directors of the company believe that it is appropriate to adopt the going concern basis in preparing the financial statements for a period up to 31 July 2027.”

Group structure

1. RANIR (HOLDINGS) LIMITED · parent
   1. Ranir Limited 100% · United Kingdom · Dormant
   2. Totalcare International Corp. 100% · British Virgin Islands · Holding company
   3. Ranir Changshu Oral Care Co. Ltd 100% · China · Oral care manufacturing
   4. Solent Oral Care Limited 100% · United Kingdom · Dormant
   5. Solent Dental Company Limited 100% · Hong Kong · Oral care sales and marketing

Significant events

• “Ranir Limited and Solent Oral Care Limited entered liquidation on 14 November 2022. As of 31 December 2025, the liquidations are ongoing and are expected to be completed within 12 months from the date of approval of these financial statements.”
• “On 20 April 2022 the company was registered as guarantor to a fixed and floating loan facility granted by JP Morgan Chase Bank N.A. The loan facility was secured by the ultimate parent company Perrigo Company Plc to fund the acquisition of the French consumer healthcare company, HRA Pharma, from Astorg and Goldman Sachs Asset Management.”
• “On the 12 March 2026, the directors paid a dividend of $1,734,850 to its immediate parent company.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.